Bilcare Limited Announces Director Changes and Board Committee Reconstitution
Bilcare Limited announced the cessation of Mrs. Madhuri Vaidya as Independent Director effective April 26, 2026, upon completion of her second five-year term. The Board appointed Advocate Ashwini Ashok Hasabnis as Non-Executive Independent Woman Director for five years from April 25, 2026, subject to shareholder approval. The company also reconstituted its Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee effective April 25, 2026.

*this image is generated using AI for illustrative purposes only.
Bilcare Limited has announced key changes to its board composition and committee structure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company disclosed that Mrs. Madhuri Vaidya (DIN: 08483512) will cease to hold the position of Independent Director upon completion of her second term at the close of business hours on April 26, 2026. Mrs. Vaidya was initially appointed for her second five-year term effective from April 26, 2021. The Board of Directors and Management expressed their appreciation for her valuable contributions during her tenure as an Independent Director.
In a related development, the Board of Directors, based on recommendations from the Nomination & Remuneration Committee, approved the appointment of Advocate Ashwini Ashok Hasabnis (DIN: 7766525) as an Additional Director in the category of Non-Executive Independent Woman Director. The appointment is for a first term of five consecutive years effective from April 25, 2026, subject to approval by the shareholders. The company confirmed that Advocate Hasabnis has not been debarred from holding the office of Director by any order from SEBI or other authorities. Shareholder approval will be sought through Postal Ballot or General Meeting, with details to be communicated in due course.
Advocate Ashwini Ashok Hasabnis brings over two decades of legal experience to the role. She holds a B.A., LL.B. degree and is enrolled with the Bar Council of Maharashtra and Goa. Her specialization includes civil and consumer law matters, arbitration proceedings, banking and finance-related disputes, and legal documentation. She has served as a legal advisor to corporates and banking institutions, providing guidance on contractual matters, documentation, and regulatory compliance.
The Board has also approved the reconstitution of three key committees effective from April 25, 2026. The Audit Committee will be chaired by Mr. Rajesh Devene (Independent Director), with Adv. Ashwini Hasabnis (Independent Director) and Mr. Shreyans Bhandari as members. The Nomination and Remuneration Committee will also be chaired by Mr. Rajesh Devene, with Ms. Alka Sagar (Independent Director) and Adv. Ashwini Hasabnis (Independent Director) serving as members. The Stakeholders Relationship Committee composition includes Mr. Rajesh Devene as Chairperson (Independent Director), Ms. Alka Sagar (Independent Director), and Mr. Shreyans Bhandari as members.
Director Appointment Details
| Particulars | Details |
|---|---|
| Name | Advocate Ashwini Ashok Hasabnis |
| DIN | 7766525 |
| Category | Non-Executive Independent Woman Director |
| Appointment Date | 25 April 2026 |
| Term | Five years subject to shareholders approval |
| Qualification | B.A., LL.B. |
| Experience | Over two decades in legal practice |
Board Committee Composition (Effective 25 April 2026)
| Committee | Chairperson | Members |
|---|---|---|
| Audit Committee | Mr. Rajesh Devene | Adv. Ashwini Hasabnis, Mr. Shreyans Bhandari |
| Nomination and Remuneration Committee | Mr. Rajesh Devene | Ms. Alka Sagar, Adv. Ashwini Hasabnis |
| Stakeholders Relationship Committee | Mr. Rajesh Devene | Ms. Alka Sagar, Mr. Shreyans Bhandari |
Historical Stock Returns for Bilcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.61% | -0.94% | -0.94% | -0.94% | -0.94% | -0.94% |
How might Advocate Hasabnis's legal expertise in banking and finance disputes influence Bilcare's strategic decisions regarding regulatory compliance and risk management?
What impact could the board restructuring have on Bilcare's corporate governance ratings and investor confidence in the pharmaceutical packaging sector?
Will the new independent director's specialization in arbitration and corporate advisory services signal potential changes in Bilcare's approach to business partnerships or dispute resolution?






























